Uploading C:\Program Files\Stnexp\Queries\10510333.str



chain nodes :
18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
3-19 6-13 11-14 15-18 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-15
14-16
15-17 16-17
exact/norm bonds :
13-14 13-15 14-16 15-17 16-17 19-20
exact bonds :
3-19 6-13 11-14 15-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 full
FULL SEARCH INITIATED 08:36:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1043 TO ITERATE

100.0% PROCESSED     1043 ITERATIONS                                 162 ANSWERS
SEARCH TIME: 00.00.01

L2          162 SEA SSS FUL L1

=> d l2 1-10

L2   ANSWER 1 OF 162  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   1027903-23-6  REGISTRY
ED   Entered STN:  13 Jun 2008
CN   INDEX NAME NOT YET ASSIGNED
MF   C17 H17 N3 O6 S2
SR   Other Sources
       Database: ChemSpider (ChemZoo, Inc.)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 2 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1026800-82-7 REGISTRY
ED Entered STN: 09 Jun 2008
CN Benzenesulfonamide, 4-[5-methyl-3-(2,4,6-trimethoxyphenyl)-4-isoxazolyl]-
(CA INDEX NAME)
MF C19 H20 N2 O6 S
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 3 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 958643-42-0 REGISTRY
ED Entered STN: 18 Dec 2007
CN γ-Cyclodextrin, compd. with 4-(5-methyl-3-phenyl-4-
isoxazolyl)benzenesulfonamide (6:1) (CA INDEX NAME)
FS STEREOSEARCH
MF C48 H80 O40 . 1/6 C16 H14 N2 O3 S

SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 181695-72-7
CMF C16 H14 N2 O3 S



CM 2

CRN 17465-86-0
CMF C48 H80 O40





1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 958643-41-9 REGISTRY
ED Entered STN: 18 Dec 2007

CN β-Cyclodextrin, compd. with 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (6:1) (CA INDEX NAME)
FS STEREOSEARCH
MF C42 H70 O35 . 1/6 C16 H14 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 181695-72-7
CMF C16 H14 N2 O3 S



CM 2

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.





1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 943600-05-3 REGISTRY
ED Entered STN: 30 Jul 2007
CN Benzenesulfonamide, 4-[3-(2-chlorophenyl)-5-methyl-4-isoxazolyl]- (CA INDEX NAME)
MF C16 H13 Cl N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 937250-85-6 REGISTRY
ED Entered STN: 14 Jun 2007
CN Acetamide, N-(4-hydroxyphenyl)-, mixt. with 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (CA INDEX NAME)
OTHER NAMES:
CN Valcox plus
CN Valeron plus
MF C16 H14 N2 O3 S . C8 H9 N O2
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 181695-72-7
CMF C16 H14 N2 O3 S



CM 2

CRN 103-90-2
CMF C8 H9 N O2



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 935681-80-4 REGISTRY
ED Entered STN: 23 May 2007
CN β-Cyclodextrin, compd. with 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (1:?) (CA INDEX NAME)
FS STEREOSEARCH
MF C42 H70 O35 . x C16 H14 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 181695-72-7
CMF C16 H14 N2 O3 S



CM 2

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 887258-63-1 REGISTRY
ED Entered STN: 08 Jun 2006
CN 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide, mixt. with 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (9CI) (CA INDEX NAME)
MF C16 H14 N2 O3 S . C7 H8 Cl N3 O4 S2
CI MXS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 181695-72-7
CMF C16 H14 N2 O3 S



CM 2

CRN 58-93-5
CMF C7 H8 Cl N3 O4 S2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 877140-46-0 REGISTRY
ED Entered STN: 17 Mar 2006
CN β-Cyclodextrin, compd. with 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C42 H70 O35 . C16 H14 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 181695-72-7
CMF C16 H14 N2 O3 S



CM 2

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.





2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 162 REGISTRY COPYRIGHT 2008 ACS on STN
RN 862126-46-3 REGISTRY
ED Entered STN: 30 Aug 2005
CN Benzenesulfonamide, 4-[5-methyl-3-(2,4,6-trimethylphenyl)-4-isoxazolyl]-
(CA INDEX NAME)
MF C19 H20 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l2 and valdecoxib?
4 VALDECOXIB?
L3 3 L2 AND VALDECOXIB?

=> d l3 1-3

L3 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 676458-08-5 REGISTRY
ED Entered STN: 22 Apr 2004
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, sodium salt (1:1)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, monosodium salt

(9CI)
OTHER NAMES:
CN Valdecoxib sodium
MF C16 H14 N2 O3 S . Na
SR CA
LC STN Files: CA, CAPLUS
CRN (181695-72-7)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 676458-07-4 REGISTRY
ED Entered STN: 22 Apr 2004
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, potassium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, monopotassium salt (9CI)
OTHER NAMES:
CN Valdecoxib potassium
MF C16 H14 N2 O3 S . K
SR CA
LC STN Files: CA, CAPLUS
CRN (181695-72-7)



● K

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181695-72-7 REGISTRY
ED Entered STN: 10 Oct 1996
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)
OTHER NAMES:
CN 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
CN Bextra
CN SC 65872
CN Valdecoxib
CN Valecoxib
CN Valus
CN Valz
MF C16 H14 N2 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

837 REFERENCES IN FILE CA (1907 TO DATE)
33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
844 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s valdecoxib
L4 4 VALDECOXIB

=> d l4 1-4

L4 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN 676458-08-5 REGISTRY
ED Entered STN: 22 Apr 2004
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, monosodium salt (9CI)
OTHER NAMES:
CN Valdecoxib sodium
MF C16 H14 N2 O3 S . Na
SR CA
LC STN Files: CA, CAPLUS
CRN (181695-72-7)



● Na

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN 676458-07-4 REGISTRY
ED Entered STN: 22 Apr 2004
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, potassium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, monopotassium salt (9CI)

OTHER NAMES:
CN Valdecoxib potassium
MF C16 H14 N2 O3 S . K
SR CA
LC STN Files: CA, CAPLUS
CRN (181695-72-7)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181695-81-8 REGISTRY
ED Entered STN: 10 Oct 1996
CN Benzenesulfonamide, 4-[5-(hydroxymethyl)-3-phenyl-4-isoxazolyl]- (CA INDEX NAME)
OTHER NAMES:
CN 1-Hydroxyvaldecoxib
CN SC 66905
MF C16 H14 N2 O4 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

54 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
54 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181695-72-7 REGISTRY
ED Entered STN: 10 Oct 1996
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)
OTHER NAMES:
CN 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
CN Bextra
CN SC 65872
CN Valdecoxib
CN Valecoxib
CN Valus
CN Valz
MF C16 H14 N2 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

837 REFERENCES IN FILE CA (1907 TO DATE)
33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
844 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	224.96	225.17

FILE 'CAPLUS' ENTERED AT 08:39:49 ON 23 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Jun 2008 VOL 148 ISS 26
FILE LAST UPDATED: 22 Jun 2008 (20080622/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l4
L5         846 L4

=> s l5 and ?crystal?
         571556 ?CRYST
        2075241 ?CRYSTAL?
         571556 ?CRYST
         373142 CRYST
           1802 CRYSTS
         374411 CRYST
                  (CRYST OR CRYSTS)
         143102 ?CRYSTD
          94897 CRYSTD
          27466 ?CRYSTG
          20979 CRYSTG
         324049 ?CRYSTN
         251430 CRYSTN
           2463 CRYSTNS
         252759 CRYSTN
                  (CRYSTN OR CRYSTNS)
        2531614 ?CRYSTAL?
                  (?CRYSTAL? OR ?CRYST OR CRYST OR ?CRYSTD OR CRYSTD OR ?CRYSTG
                  OR CRYSTG OR ?CRYSTN OR CRYSTN)
L6          77 L5 AND ?CRYSTAL?

=> s l6 and polymorp?
         234268 POLYMORP?
L7           9 L6 AND POLYMORP?

=> d l7 1-9 ibib abs hitstr

L7   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:74254  CAPLUS <<LOGINID::20080623>>
DOCUMENT NUMBER:          148:175738
TITLE:                    Compositions and methods comprising bicifadine for the
                          treatment of chronic pain conditions
INVENTOR(S):              Skolnick, Phil; Stern, Warren
PATENT ASSIGNEE(S):       Dov Pharmaceutical, Inc., USA
SOURCE:                   PCT Int. Appl., 59pp.
```

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2008008474	A2	20080117	WO 2007-US15964		20070711
US 20080014272	A1	20080117	US 2007-775721		20070710
PRIORITY APPLN. INFO.:			US 2006-830412P	P	20060711
			US 2007-775721	A	20070710

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AB The present invention relates to methods, pharmaceutical compns. and kits for treating osteoarthritis-associated pain, inflammation and improving function in a patient comprising a first therapeutic agent which comprises bicifadine or a pharmaceutically acceptable salt, enantiomer, solvate, hydrate, polymorph or prodrug thereof and a second therapeutic agent which comprises a non-steroidal anti-inflammatory drug or derivative thereof. Thus, treatment with bicifadine or ibuprofen alone was no different than treatment with placebo in reducing osteoarthritis-associated pain as measured by the visual analog scale in humans. In contrast, treatment with the combination of bicifadine and ibuprofen resulted in a significant decrease in osteoarthritis-associated pain levels.

IT 181695-72-7, Valdecoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods comprising bicifadine for treatment of chronic pain conditions)

RN 181695-72-7 CAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1483225 CAPLUS <<LOGINID::20080623>>
DOCUMENT NUMBER: 148:449003
TITLE: Conformational aspects and interaction studies of heterocyclic drugs
AUTHOR(S): Ponnuswamy, M. N.; Gromiha, M. Michael; Sony, S. M. Malathy; Saraboji, K.
CORPORATE SOURCE: Department of Crystallography and Biophysics, University of Madras, Chennai, 600 025, India
SOURCE: Topics in Heterocyclic Chemistry (2006), 3(QSAR and Molecular Modeling Studies in Heterocyclic Drugs I), 81-147
CODEN: THCOA6; ISSN: 1861-9282
PUBLISHER: Springer GmbH
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Drug discoveries require the iterative synthesis-along with structural studies-of numerous individual analogs of biol. and medicinally active compds. Over half of all known compds. and a large number of pharmaceutical products are heterocyclic in nature. The pharmacol. activity of drugs depends mainly on interaction with their biol. targets, which have a complex three-dimensional structure, and mol. recognition is guided by the nature of the intermol. interactions. Furthermore, the drug's polymorphic nature also adversely affects its abilities. In order to address these factors, the stereochem. anal. of various piperidine and azepine derivs., weak π-interaction anal. of isoxazole, imidazole, indole, quinoline and triazole and polymorphic anal. of two com. drugs, valdecoxib and sildenafil citrate were carried out. Only the crystal structures were used for these analyses, of which the piperidine and azepine derivs., valdecoxib and sildenafil citrate were solved by our group. To understand the structure-activity relationship, the results of these studies were correlated with the crystal structure of their resp. drug mols. that are found in complex with the receptors. Stereochem. anal. showed that the ring conformation and orientation of the substituents correlate well with the active conformation of the drug. The π-systems prefer to form an offset stacking π...π interaction geometry similar to the phenylalanine-phenylalanine interactions in proteins. In the polymorphic anal. one of the crystal conformations of valdecoxib proved to have better interaction with its receptor indicating higher activity.

IT 181695-72-7, Valdecoxib
RL: PRP (Properties)
(conformational aspects and interaction studies of heterocyclic drugs)

RN 181695-72-7 CAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:300882 CAPLUS <<LOGINID::20080623>>
DOCUMENT NUMBER: 147:350747
TITLE: Benzoquinolizine-2-carboxylic acid containing compositions
INVENTOR(S): Saoji, Dilip Gopalkrishna; Nagori, Rajendra N.; Shukla, Milind Chintaman; Bhagwat, Sachin Subhash; Gupte, Shrikant Vinayak; Patel, Mahesh Vithalbhai; Jha, Rasendrakumar; Kukreja, Anil; De Souza, Noel John
PATENT ASSIGNEE(S): Wockhardt Limited, India
SOURCE: Indian Pat. Appl., 34pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2003MU01334	A	20060120	IN 2003-MU1334	20031231

PRIORITY APPLN. INFO.: IN 2003-MU1334 20031231

AB This invention relates to topical compns. of an antibacterial benzoquinolizine-2-carboxylic acid, incorporated either as the single therapeutic ingredient in hitherto undescribed pharmaceutical compns., or as an ingredient in novel combination with at least one agent selected from a retinoid, an antifungal agent, another antibacterial compound and/or a steroid/non-steroid anti inflammatory agent, to processes for preparation of the compns., to use of the compns. in preparation of a medicament, and to a method of therapeutic or prophylactic use of such a composition for the treatment of dermal, ophthalmic, otic and nasal infections, with or without attendant inflammation.

IT 181695-72-7, Valdecoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzoquinolizine carboxylic acid-containing topical compns.)
RN 181695-72-7 CAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:88439 CAPLUS <<LOGINID::20080623>>
DOCUMENT NUMBER: 146:169380
TITLE: Novel pharmaceutical modified release dosage forms comprising cyclooxygenase inhibitor

INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Singh, Sukhjeet; Talwar, Munish
PATENT ASSIGNEE(S): Panacea Biotec Ltd., India
SOURCE: PCT Int. Appl., 38pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007010559	A2	20070125	WO 2006-IN258	20060719
WO 2007010559	A3	20070920		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005DE01899	A	20070824	IN 2005-DE1899	20050720
AU 2006271150	A1	20070125	AU 2006-271150	20060719
CA 2614850	A1	20070125	CA 2006-2614850	20060719
EP 1906933	A2	20080409	EP 2006-780539	20060719
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
KR 2008032209	A	20080414	KR 2008-704111	20080220

PRIORITY APPLN. INFO.: IN 2005-DE1899 A 20050720
WO 2006-IN258 W 20060719

AB Pharmaceutical modified release dosage form comprising at least one cyclooxygenase inhibitor or its salts, esters, prodrugs, solvates, hydrates, or derivs. thereof as active agent, with a carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than 60% of the cyclooxygenase enzyme inhibitor in 1 h and not less than 75% of the cyclooxygenase enzyme inhibitor after 12 h when tested in accordance with the dissoln. method using distilled water with 2.0% sodium lauryl sulfate as the dissoln. medium or in accordance with a dissoln. method employing pH 7.0 phosphate buffer with 2.0% sodium lauryl sulfate as the dissoln. medium or in accordance with a dissoln. method employing 0.001N HCl with 1.0% sodium lauryl sulfate as dissoln. medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (Cmax) after at least about 1 h of administration of the dosage form. The present invention also provides process of preparing such dosage form compns. and prophylactic and/or therapeutic methods of using such dosage forms.

IT 181695-72-7, Valdecoxib
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical modified release dosage forms comprising cyclooxygenase inhibitor)

RN 181695-72-7 CAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1330315 CAPLUS <<LOGINID::20080623>>
DOCUMENT NUMBER: 144:57579
TITLE: Process for obtaining form A of valdecoxib suitable for pharmaceutical formulations
INVENTOR(S): Thakashinamoorthy, Chandiran; Jesudoss, Mercy Gnanadeepam; Hariharasubramanian, Meera; Seetharaman, Subramanian Sankara
PATENT ASSIGNEE(S): India
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005120499	A1	20051222	WO 2004-IN162	20040610

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2004-IN162 20040610

AB The invention provides for a reactive crystallization procedure for obtaining polymorphic Form A of valdecoxib with desirable particle size characteristics without milling, making it useful as an active ingredient in the preparation of pharmaceutical composition For example, valdecoxib 250 g was added in to aqueous sodium hydroxide 5000 mL at 500 C and stirred. The content was heated to 60° C to get a clear solution The pH of the solution after dissoln. was 11.6. To the alkaline solution was added aqueous hydrochloric acid 1280 mL through dip pipe. During the acidification the product ppts. from the solution of pH 1.5. The precipitated product was filtered

immediately and the product was then washed with water 6500 mL. The product obtained was dried at 70 to 75° C under reduced pressure till the water content in the product was less then 0.3 % weight/weight to yield the product 235 g.

IT 181695-72-7, Valdecoxib
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(process for obtaining form A of valdecoxib suitable for pharmaceutical formulations)

RN 181695-72-7 CAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:823681 CAPLUS <<LOGINID::20080623>>
DOCUMENT NUMBER: 143:216704
TITLE: Crystalline polymorphs of a CXC-chemokine receptor ligand
INVENTOR(S): Hu, Mengwei; Yu, Younong; Dwyer, Michael; Taveras, Arthur G.; Kim-Meade, Agnes; Yin, Jianguo; Fu, Xiaoyong; Mcallister, Timothy; Zhang, Shuyi; Klopfer, Kevin
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075447	A1	20050818	WO 2005-US3414	20050128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005210504	A1	20050818	AU 2005-210504		20050128
CA 2554709	A1	20050818	CA 2005-2554709		20050128
US 20050192345	A1	20050901	US 2005-45772		20050128
EP 1723131	A1	20061122	EP 2005-712748		20050128
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 1914187	A	20070214	CN 2005-80003507		20050128
BR 2005007329	A	20070703	BR 2005-7329		20050128
JP 2007519751	T	20070719	JP 2006-551613		20050128
MX 2006PA08599	A	20060828	MX 2006-PA8599		20060728
IN 2006CN02800	A	20070608	IN 2006-CN2800		20060728
NO 2006003841	A	20061027	NO 2006-3841		20060829
PRIORITY APPLN. INFO.:			US 2004-540487P	P	20040130
			WO 2005-US3414	W	20050128

AB The present invention relates to 4 distinct crystalline polymorphs of a monohydrate of 2-hydroxy-N,N-dimethyl-3-[[2-[[1-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide. These 4 polymorphic forms, herein referred to as Forms I, II, III and IV are active as a CXC-chemokine receptor ligands. The invention is further directed to formulations, methods of treatment, and processes of synthesis of these polymorphic forms.

IT 181695-72-7, Valdecoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystalline polymorphs of CXC-chemokine receptor ligand)

RN 181695-72-7 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:565095 CAPLUS <<LOGINID::20080623>>

DOCUMENT NUMBER: 141:111581

TITLE: Benzoquinolizine-2-carboxylic acid-containing compositions

INVENTOR(S): Saoji, Dilip G.; Nagori, Rajendra N.; Shukla, Milind C.; Bhagwat, Sachin S.; Gupte, Shrikant V.; Patel, Mahesh V.; Jha, Rasendrakumar; Kukreja, Anil; De Souza, Noel J.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058262	A1	20040715	WO 2003-IN422	20031231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2002MU01170	A	20050128	IN 2002-MU1170	20021231
CA 2512190	A1	20040715	CA 2003-2512190	20031231
AU 2003302305	A1	20040722	AU 2003-302305	20031231
US 20040176337	A1	20040909	US 2003-749933	20031231
EP 1589972	A1	20051102	EP 2003-810861	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: IN 2002-MU1170 A 20021231
WO 2003-IN422 W 20031231

OTHER SOURCE(S): MARPAT 141:111581

AB The invention relates to topical compns. of an antibacterial benzoquinolizine-2-carboxylic acid, incorporated either as the single therapeutic ingredient in hitherto undescribed pharmaceutical compns., or as an ingredient in novel combination with at least one agent selected from a retinoid, an antifungal agent, another antibacterial compound and/or a steroidal/nonsteroidal anti-inflammatory agent. Processes for preparation of the compns., the use of the compns. and a method of therapeutic or prophylactic use of such a composition for the treatment of dermal, ophthalmic, otic and nasal infections, with or without attendant inflammation are disclosed. Thus, a gel contained RS-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid 1.00, Carbopol 1.20, NaOH 0.112, diethanolamine 0.36, disodium edetate 0.10, sodium sulfite 0.05, and water qs to 100%.

IT 181695-72-7, Valdecoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzoquinolizinecarboxylic acid-containing topical compns.)

RN 181695-72-7 CAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:269999 CAPLUS <<LOGINID::20080623>>
DOCUMENT NUMBER: 140:309372
TITLE: Pharmaceutical compositions with improved dissolution
INVENTOR(S): Remenar, Julius; Peterson, Matthew; Almarsson, Om; Guzman, Hector; Chen, Hongming; Tawa, Mark; Oliveira, Mark
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026235	A2	20040401	WO 2003-US28982	20030916
WO 2004026235	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003267231	A1	20040408	AU 2003-267231	20030916
CA 2511881	A1	20040722	CA 2003-2511881	20031224
WO 2004061433	A1	20040722	WO 2003-US41273	20031224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003303591	A1	20040729	AU 2003-303591	20031224
EP 1579198	A1	20050928	EP 2003-808567	20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP	2006517527	T	20060727	JP 2005-508617	20031224
WO	2004060347	A2	20040722	WO 2003-US41642	20031229
WO	2004060347	A3	20041104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003300452	A1	20040729	AU 2003-300452	20031229
US	20060052432	A1	20060309	US 2005-528244	20050317
US	20060134198	A1	20060622	US 2005-541216	20050629
US	20060140985	A1	20060629	US 2005-541703	20050708

PRIORITY APPLN. INFO.:

US 2002-412459P	P	20020920
US 2002-426275P	P	20021114
US 2002-427086P	P	20021115
US 2002-429515P	P	20021126
US 2002-437516P	P	20021230
US 2003-456027P	P	20030318
US 2002-232589	A	20020903
US 2003-439283P	P	20030110
US 2003-441335P	P	20030121
US 2003-451213P	P	20030228
US 2003-378956	A	20030303
US 2003-456608P	P	20030321
US 2003-459501P	P	20030401
US 2003-449307	A	20030530
US 2003-601092	A	20030620
WO 2003-US19574	A	20030620
US 2003-486713P	P	20030711
US 2003-487064P	P	20030711
US 2003-637829	A	20030808
WO 2003-US27772	A	20030904
US 2003-660202	A	20030911
WO 2003-US28982	W	20030916
WO 2003-US41273	W	20031224
WO 2003-US41642	W	20031229
WO 2004-US400	W	20040108

AB The invention relates to methods of screening mixts. containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissoln. and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer. For example, celecoxib sodium salt was prepared from 126.3 mg of celecoxib in isopropanol and sodium ethoxide (21% ethanol solution). Water was added to a 1:4 mixture of celecoxib sodium salt and polyvinylpyrrolidone to obtain a clear solution The solution was stable for at least 15 min, after which time, crystals of neutral celecoxib began to form. Crystalline neutral celecoxib did not dissolve when added to aqueous polyvinylpyrrolidone or when water was added to a dry blend of neutral crystalline celecoxib and polyvinylpyrrolidone.

IT 181695-72-7, Valdecoxib 676458-07-4, Valdecoxib potassium 676458-08-5, Valdecoxib sodium
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. with improved dissoln. and bioavailability of drugs with low solubility)

RN 181695-72-7 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)



RN 676458-07-4 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, potassium salt (1:1) (CA INDEX NAME)



RN 676458-08-5 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, sodium salt (1:1) (CA INDEX NAME)



● Na

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:107158 CAPLUS <<LOGINID::20080623>>
DOCUMENT NUMBER: 136:161365
TITLE: Aldosterone antagonist-cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
INVENTOR(S): Rocha, Ricardo; Zack, Marc D.; McMahon, Ellen G.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 273 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009759	A2	20020207	WO 2001-US23601	20010726
WO 2002009759	A3	20021128		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2415078	A1	20020207	CA 2001-2415078	20010726
EP 1303308	A2	20030423	EP 2001-961746	20010726
EP 1303308	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030125312	A1	20030703	US 2001-915784	20010726
US 6716829	B2	20040406		
JP 2004505060	T	20040219	JP 2002-515311	20010726
AT 338566	T	20060915	AT 2001-961746	20010726
ES 2269442	T3	20070401	ES 2001-961746	20010726
CA 2469950	A1	20030626	CA 2001-2469950	20011213
AU 2002249804	A1	20030630	AU 2002-249804	20011213
EP 1453522	A1	20040908	EP 2001-998044	20011213

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR	2001017195	A	20050209	BR 2001-17195		20011213
CN	1582154	A	20050216	CN 2001-823946		20011213
JP	2005516015	T	20050602	JP 2003-552305		20011213
US	20030191100	A1	20031009	US 2002-243876		20020913
MX	2004PA05803	A	20041101	MX 2004-PA5803		20040614
US	20070191324	A1	20070816	US 2006-613879		20061220
PRIORITY APPLN. INFO.:				US 2000-221364P	P	20000727
				US 2001-261497P	P	20010112
				US 1999-164390P	P	19991109
				US 2000-211064P	P	20000613
				US 2000-211250P	P	20000613
				US 2000-211253P	P	20000613
				US 2000-211264P	P	20000613
				US 2000-211311P	P	20000613
				US 2000-211340P	P	20000613
				US 2000-211451P	P	20000613
				US 2000-211459P	P	20000613
				US 2000-221358P	P	20000727
				US 2000-233056P	P	20000914
				US 2000-709253	A2	20001108
				US 2000-712543	A1	20001114
				US 2000-713348	B2	20001114
				US 2001-261352P	P	20010112
				WO 2001-US23601	W	20010726
				WO 2001-US48419	W	20011213
				US 2003-682527	A1	20031009

OTHER SOURCE(S): MARPAT 136:161365

AB Combinations of aldosterone blockers and Cyclooxygenase-2 inhibitors useful in the treatment of inflammation-related cardiovascular disorders are disclosed.

IT 181695-72-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aldosterone antagonist-cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders)

RN 181695-72-7 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (CA INDEX NAME)